RA Capital discloses 23.8% stake in Parabilis Medicines post-IPO, investing $497M
PBLS is trading near its 52-week low of $24.51 (5.5% above the low) on light trading volume (0.3× avg).
Summary
RA Capital Management, a major healthcare fund, has disclosed a 23.8% beneficial ownership stake in Parabilis Medicines, Inc. following its recent IPO, representing a total investment of nearly $500 million.
Key Events · Ownership and Investor Activity · PBLS
-
Major Institutional Stake Established
RA Capital Management, L.P. and its affiliates disclosed a 23.8% beneficial ownership stake in Parabilis Medicines, Inc., making them a foundational investor.
-
Significant Investment Post-IPO
The Reporting Persons invested approximately $497.3 million, including pre-IPO preferred stock conversions and $423.8 million in common stock purchased at the IPO price of $20.00 per share.
-
Timing Aligns with IPO Close
This initial Schedule 13D filing establishes RA Capital's significant position immediately following the company's upsized initial public offering, which closed on June 11, 2026.
-
Board Representation and Lock-up
A partner of RA Capital serves on the board of directors, and the fund is subject to a 180-day lock-up agreement from the IPO date, restricting share sales.
Analysis · PBLS · Life Sciences
This initial Schedule 13D filing reveals that RA Capital Management, a prominent healthcare fund, has taken a substantial 23.8% beneficial ownership stake in Parabilis Medicines immediately following its upsized IPO. The nearly $500 million investment, including a $423.8 million purchase at the IPO price of $20.00 per share, represents a significant vote of confidence from a major institutional investor for the newly public company. This establishes a foundational investor with board representation, providing stability and validation for the company's prospects.
How filings like this one have moved
In the 30 days to Oct 30, 2026, 48.8% of the 217 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PBLS was trading at $25.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.1B. The 52-week trading range was $24.51 to $34.47. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.